Validation of cognitive screening questionnaire for neurological disorders (CSQND) for screening of cognitive complaints among patients with multiple sclerosis

被引:0
|
作者
Fouad, Amr [1 ]
Shawky, Ahmed [1 ]
Farghaly, Marwa [1 ]
Naseer, Maged Abdel [1 ]
Hegazy, Mohamed, I [1 ]
机构
[1] Cairo Univ, Fac Med, Dept Neurol, Cairo, Egypt
关键词
Multiple sclerosis; Cognition; CSQND; Questionnaire; IMPAIRMENT; DYSFUNCTION; DISABILITY; MRI;
D O I
10.1186/s41983-022-00529-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background The prevalence of cognitive impairment (CI) can reach up to 65% among multiple sclerosis (MS) patients. Self-administered screening questionnaires can offer a valuable solution for screening MS patients for cognitive complaints. The cognitive screening questionnaire for neurological disorders (CSQND) is an Arabic self-administered questionnaire that has been developed to screen patients with various neurological disorders attending neurology clinics. The aim of this study was to assess cognitive complaints and to validate the CSQND as a screening tool among Egyptian MS patients. Results Four-hundred MS patients and 400 controls were included in this study. All 400 patients and 400 controls were subjected to the CSQND, only 50 out of the 400 patients and 50 out of the 400 controls retook the CSQND 1 week later to establish test-retest reliability. Fifty patients and 50 controls were assessed by the symbol digit modalities test (SDMT) to establish concurrent validity. Thirty-four percent of patients complained of memory problems, 51% complained of concentration difficulties, 34% complained of language difficulties and 22.5% complained of space and time disorientation. Multiple sclerosis patients had significantly more cognitive complaints (12.4 +/- 12.6) compared to controls (6.2 +/- 6.8) when screened using the CSQND (P < 0.000001). Total scores of CSQND were positively significantly correlated to age at onset, total disease duration, EDSS scores and total number of relapses, (r = 0.14; 0.275; 0.3; 0.167, respectively), P < 0.05 for all. Agreement was found between CSQND results and the SDMT results, where the line of equality lied within the 95% confidence interval of the mean. A significant positive correlation was found between the CSQND results at the first application and upon retesting both in patients (R = 0.9, P = 0.0001) and controls (R = 0.85, P = 0.0001). Conclusions The CSQND was found to be a simple, valid, and reliable self-administered questionnaire to screen for cognitive complaints in MS patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Validation of a brief cross-cultural cognitive screening test in Multiple Sclerosis
    Delgado-Alvarez, Alfonso
    Delgado-Alonso, Cristina
    Goudsmit, Miriam
    Jose Gil, Maria
    Diez-Cirarda, Maria
    Valles-Salgado, Maria
    Montero-Escribano, Paloma
    Hernandez-Lorenzo, Laura
    Matias-Guiu, Jorge
    Matias-Guiu, Jordi A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [22] Construction of a Questionnaire for Complaints of Cognitive Disturbances in Patients with Mental Disorders
    Beblo, Thomas
    Kunz, Miriam
    Brokate, Barbara
    Scheurich, Armin
    Weber, Bernhard
    Albert, Anita
    Richter, Petra
    Lautenbacher, Stefan
    ZEITSCHRIFT FUR NEUROPSYCHOLOGIE, 2010, 21 (03) : 143 - 151
  • [23] Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
    Zaegel-Faucher, Olivia
    Laroche, Helene
    Tixier, Maelys
    Morisseau, Victoire
    Obry-Roguet, Veronique
    Poizot-Martin, Isabelle
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2021, 33 (03): : 389 - 397
  • [24] Screening ability of cognitive function by two measures in patients with multiple sclerosis
    Kawada, Tomoyuki
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 391 : 153 - 153
  • [25] Screening for functional neurological disorders by questionnaire
    Shipston-Sharman, Oliver
    Hoeritzauer, Ingrid
    Edwards, Mark
    Reubere, Markus
    Carson, Alan
    Stone, Jon
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2019, 119 : 65 - 73
  • [26] Validation of a dystonia screening questionnaire Testing in a cohort of mixed neurological disorders
    Snik, Dorinda
    Hoffland, Britt Sofie
    Aguirregomozcorta, Maria
    Schwingenschuh, Petra
    Bhatia, Kailash P.
    van de Warrenburg, Bart P.
    Edwards, Mark J.
    PARKINSONISM & RELATED DISORDERS, 2010, 16 (09) : 620 - 622
  • [27] Validation of the Spanish-language version of the Montreal Cognitive Assessment as a screening test for cognitive impairment in multiple sclerosis
    Gomez-Moreno, S. M.
    Cuadrado, M. L.
    Cruz-Orduna, I
    Martinez-Acebesa, E. M.
    Gordo-Manas, R.
    Fernandez-Perez, C.
    Garcia-Ramos, R.
    NEUROLOGIA, 2022, 37 (09): : 726 - 734
  • [28] Online cognitive screening for people with Multiple Sclerosis: Is it inclusive?
    Taylor, Lauren
    Swain, Polly
    Morris, Haley
    Ponda, Dwiti
    Price, Laura
    Stennett, Andrea
    Allen-Philbey, Kimberley
    Tallantyre, Emma
    Schmierer, Klaus
    Evangelou, Nikos
    das Nair, Roshan
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 748 - 749
  • [29] Screening for Cognitive Impairment in Multiple Sclerosis with MOCA Test
    Aksoy, Selma
    Timer, Emin
    Mumcu, Sibel
    Akgun, Mucella
    Kivrak, Elifnur
    Orken, Dilek Necioglu
    TURKISH JOURNAL OF NEUROLOGY, 2013, 19 (02) : 52 - 55
  • [30] Adaptation and Validation of the Psychological Consequences of Screening Questionnaire (PCQ) for Cognitive Screening in Primary Care
    Lovett, Rebecca M.
    Filec, Sarah
    Hurtado, Jeimmy
    Kwasny, Mary
    Sideman, Alissa
    Persell, Stephen D.
    Possin, Katherine
    Wolf, Michael
    MEDICAL DECISION MAKING, 2024, 44 (08) : 914 - 926